NCT02424708View on ClinicalTrials.gov

Phase IIb Study of Intranasal Glutathione in Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

April 30, 2016

Conditions
Parkinson's Disease
Interventions
DRUG

Reduced Glutathione 100mg

100mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.

DRUG

Reduced Glutathione 200mg

200mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.

DRUG

Placebo

Saline delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.

Trial Locations (2)

98028

Bastyr University, Kenmore

98195

University of Washington, Seattle

All Listed Sponsors
collaborator

Michael J. Fox Foundation for Parkinson's Research

OTHER

lead

Bastyr University

OTHER

NCT02424708 - Phase IIb Study of Intranasal Glutathione in Parkinson's Disease | Biotech Hunter | Biotech Hunter